Recurrent Pneumonitis Induced by Atezolizumab (Anti–Programmed Death Ligand 1) in NSCLC Patients Who Previously Experienced Anti-Programmed Death 1 Immunotherapy-Related Pneumonitis
Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.06.022
Full Text
Open PDFAbstract
Available in full text
Date
November 1, 2018
Authors
Publisher
Elsevier BV